WO2002096905A1 - Thiazole compounds useful as inhibitors of protein kinases - Google Patents

Thiazole compounds useful as inhibitors of protein kinases Download PDF

Info

Publication number
WO2002096905A1
WO2002096905A1 PCT/US2002/016352 US0216352W WO02096905A1 WO 2002096905 A1 WO2002096905 A1 WO 2002096905A1 US 0216352 W US0216352 W US 0216352W WO 02096905 A1 WO02096905 A1 WO 02096905A1
Authority
WO
WIPO (PCT)
Prior art keywords
iia
independently selected
ring
nitrogen
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/016352
Other languages
French (fr)
Other versions
WO2002096905A8 (en
Inventor
John Cochran
Suganthini Nanthakumar
Edmund Harrington
Jian Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to DE60214703T priority Critical patent/DE60214703T2/en
Priority to CA2446756A priority patent/CA2446756C/en
Priority to MXPA03010961A priority patent/MXPA03010961A/en
Priority to EP02737123A priority patent/EP1392684B1/en
Priority to JP2003500084A priority patent/JP4523271B2/en
Priority to HK04106666.6A priority patent/HK1065033B/en
Publication of WO2002096905A1 publication Critical patent/WO2002096905A1/en
Anticipated expiration legal-status Critical
Publication of WO2002096905A8 publication Critical patent/WO2002096905A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Definitions

  • the present invention relates to compounds that are protein kinase inhibitors, pharmaceutically acceptable compositions comprising said compounds, and methods of use thereof. More particularly, the compounds are inhibitors of GSK-3, Aurora2 , and Syk protein kinases and are useful for treating, or lessening the severity of, a variety of diseases and conditions, such as diabetes, Alzheimer's disease, stroke, proliferative disorders, and asthma.
  • Protein kinases mediate intracellular signal transduction. They do this by affecting a phosphoryl transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway.
  • kinases and pathways through which extracellular and other stimuli cause a variety of cellular responses to occur inside the cell. Examples of such stimuli include environmental and chemical stress signals (e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H 2 0 2 ) , cytokines (e.g. interleukin-1 (IL-1) and tumor necrosis factor ⁇ (TNF- ⁇ ) ) , and growth factors (e.g.
  • environmental and chemical stress signals e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H 2 0 2
  • cytokines e.g. interleukin-1 (IL-1) and tumor necrosis factor ⁇ (TNF- ⁇ )
  • growth factors e.g
  • GM-CSF granulocyte macrophage- colony-stimulating factor
  • FGF fibroblast growth factor
  • Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase comprised of ⁇ and ⁇ isoforms that are each encoded by distinct genes [Coghlan et al . , Chemistry & Biology, 7, 793-803 (2000); Kim and Kimmel, Curr. Opinion Genetics Dev. , 10, 508-514 (2000)].
  • GSK-3 has been implicated in various diseases including diabetes, Alzheimer's disease, CNS disorders such as manic depressive disorder and neurodegenerative diseases, and cardio yocete hypertrophy [WO 99/65897; WO 00/38675; and Haq et al . , J. Cell Biol . (2000) 151, 117].
  • GSK-3 may be caused by, or result in, the abnormal operation of certain cell signaling pathways in which GSK-3 plays a role.
  • GSK-3 has been found to phosphorylate and modulate the activity of a number of regulatory proteins. These include glycogen synthase which is the rate limiting enzyme necessary for glycogen synthesis, the microtubule associated protein Tau, the gene transcription factor ⁇ -catenin, the translation initiation factor elF2B, as well as ATP citrate lyase, axin, heat shock factor-1, c-Jun, c-Myc, c-Myb, CREB, and CEPB ⁇ . These diverse targets implicate GSK-3 in many aspects of cellular metabolism, proliferation, differentiation and development.
  • GSK-3 is a negative regulator of the insulin-induced signal.
  • the presence of insulin causes inhibition of GSK-3 mediated phosphorylation and deactivation of glycogen synthase.
  • the inhibition of GSK-3 leads to increased glycogen synthesis and glucose uptake [Klein et al . , PNAS, 93, 8455-9 (1996); Cross et al . , Biochem . J. , 303, 21-26 (1994); Cohen, Biochem . Soc . Trans . , 21, 555-567 (1993); Massillon et al .
  • Therapeutic inhibitors of GSK-3 are therefore potentially useful for treating diabetic patients suffering from an impaired response to insulin.
  • GSK-3 activity has also been associated with Alzheimer's disease. This disease is characterized by the well-known ⁇ -amyloid peptide and the formation of intracellular neurofibrillary tangles.
  • the neurofibrillary tangles contain hyperphosphorylated Tau protein where Tau is phosphorylated on abnormal sites. GSK-3 has been shown to phosphorylate these abnormal sites in cell and animal models. Furthermore, inhibition of GSK-3 has been shown to prevent hyperphosphorylation of Tau in cells [Lovestone et al . , Current Biology 4, 1077-86 (1994); Brownlees et al . , Neuroreport 8, 3251-55 (1997)]. Therefore, it is believed that GSK-3 activity may promote generation of the neurofibrillary tangles and the progression of Alzheimer's disease.
  • ⁇ -catenin Another substrate of GSK-3 is ⁇ -catenin which is degradated after phosphorylation by GSK-3.
  • Reduced levels of ⁇ -catenin have been reported in schizophrenic patients and have also been associated with other diseases related to increase in neuronal cell death [Zhong et al . , Nature, 395, 698-702 (1998); Takashima et al., PNAS, 90, 7789-93 (1993); Pei et al . , J. Neuropathol . Exp, 56, 70-78 (1997)].
  • Aurora-2 is a serine/threonine protein kinase that has been implicated in human cancer, such as colon, breast and other solid tumors. This kinase is involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-2 plays a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities.
  • human colon cancer tissue the aurora-2 protein has been found to be overexpressed [Bischoff et al . , EMBO J. , 17, 3052-3065 (1998); Schumacher et al . , J. Cell Biol . , 143, 1635-1646 (1998); Kimura et al . , J “ . Biol . Chem . , 272, 13766-13771 (1997) ] .
  • Syk is a tyrosine kinase that plays a critical role in Fc ⁇ RI mediated mast cell degranulation and eosiniphil activation. Accordingly, Syk kinase is implicated in various allergic disorders, in particular asthma.
  • Syk kinase is required for the prevention of eosinophil apoptosis by cytokines (using antisense) [Yousefi et al, J Exp Med 1996 ; 183 : 1407] .
  • the role of Syk in Fc ⁇ R dependent and independent response in bone marrow derived macrophages has been determined by using irradiated mouse chimeras reconstituted with fetal liver cells from Syk -/- embryos.
  • Syk deficient macrophages were defective in phagocytosis induced by Fc ⁇ R but showed normal phagocytosis in response to complement [Kiefer et al, Mol Cell Biol 1998; 18:4209].
  • aerosolized Syk antisense suppresses Syk expression and mediator release from macrophages [Stenton et al, J Immunology 2000; 164: 3790].
  • the present invention also provides a pharmaceutically acceptable composition comprising a compound of formula I .
  • the compounds and pharmaceutically acceptable compositions of the present invention are useful as inhibitors of GSK-3, Aurora-2, and Syk protein kinases. Thus, they are also useful in methods for treating or lessening the severity of a variety of disorders, such as allergic diseases, proliferative disorders, cancer, neurodegenerative disorders, and diabetes.
  • the present invention relates to a compound of formula I :
  • R 1 is selected from R, halogen, CN, N0 2 , or TR;
  • T is an optionally substituted C ⁇ -C 4 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by O, N(R), C(O), S, SO, or S0 2 ;
  • each R is independently selected from hydrogen or an optionally substituted C ⁇ - 6 aliphatic group, wherein: two R bound to the same nitrogen atom are optionally taken together with the nitrogen to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms, in addition to the nitrogen bound thereto, independently selected from nitrogen, oxygen, or sulfur;
  • Ar 1 is an optionally substituted ring selected from: (a) a 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially unsaturated, or aryl ring;
  • Ar 1 is optionally substituted by one to four substituents selected from the group consisting of:
  • each Q is indpendently selected from a valence bond or an optionally substituted C 1-6 alkylidene chain, wherein: one or two non-adjacent methylene units of Q are optionally and independently replaced by -O- , -S-,
  • each Ar 2 is an optionally substituted ring independently selected from:
  • Ar 2 is optionally substituted by one to four R 2 groups ; and each R 2 is independently selected from R, halogen, N0 2 , CN, OR, SR, N(R) 2 , NRCOR, NRCON(R) 2 , NRC0 2 R, C(0)R, C0 2 R, C0N(R) 2 , 0C(0)N(R) 2 , SOR, S0 2 R, S0 2 N(R) 2 , NRS0 2 R, NRS0 2 N(R) 2 , C(0)C(0)R, or C
  • an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.
  • aliphatic or "aliphatic group” as used herein means a straight-chain or branched C ⁇ -C 8 hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic C 3 -C 8 hydrocarbon or bicyclic C 8 -C ⁇ 2 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle” or "cycloalkyl”), that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members.
  • suitable aliphatic groups include, but are not limited to, linear or branched or alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl) alkyl, (cycloalkenyl) alkyl or (cycloalkyl) alkenyl.
  • alkyl used alone or as part of a larger moiety include both straight and branched chains containing one to twelve carbon atoms.
  • alkenyl and “alkynyl” used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve carbon atoms.
  • heteroatom means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen.
  • nitrogen includes a substitutable nitrogen of a heterocyclic ring.
  • the nitrogen in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3 , 4-dihydro-2H-pyrrolyl) , NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl) .
  • aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy” , or “aryloxyalkyl” , refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
  • aryl may be used interchangeably with the term “aryl ring”.
  • aryl also refers to heteroaryl ring systems as defined hereinbelow.
  • heterocycle means non-aromatic, monocyclic, bicyclic or tricyclic ring systems having five to fourteen ring members in which one or more ring members is a heteroatom, wherein each ring in the system contains 3 to 7 ring members.
  • heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy” , refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members.
  • heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic” .
  • An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents.
  • Suitable substituents on the unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group are selected from halogen, -R°, -0R°, -SR°, 1, 2-methylene-dioxy, 1,2- ethylenedioxy, phenyl (Ph) optionally substituted with R°, -O(Ph) optionally substituted with R°, -CH 2 (Ph) optionally substituted with R°, -CH 2 CH 2 (Ph) , optionally substituted with R°, -N0 2 , -CN, -N(R°) 2 , -NR°C(0)R°, -NR°C (O) N (R°) 2 , -
  • each R° is independently selected from hydrogen, optionally substituted C ⁇ _ 6 aliphatic, an unsubstituted 5-6 membered heteroaryl or heterocyclic ring, phenyl, -O(Ph), or -CH 2 (Ph).
  • Optional substituents on the aliphatic group of R° are selected from NH 2 , NH(C 1-4 aliphatic), N(C ⁇ _ 4 aliphatic) 2 , halogen, Ci-4 aliphatic, OH, 0(Ci- 4 aliphatic), N0 2 , CN, C0 2 H, C0 2 (C ⁇ - 4 aliphatic), O(halo C ⁇ - 4 aliphatic) , or halo C ⁇ _ 4 aliphatic.
  • Optional substituents on the aliphatic group of R * are selected from NH 2 , NH(C ⁇ - 4 aliphatic), N(C ⁇ _ aliphatic) 2 halogen, C ⁇ - 4 aliphatic, OH, 0(C ⁇ _ 4 aliphatic), N0 2 , CN, C0 2 H, C0 2 (Ci- 4 aliphatic), 0(halo C 1-4 aliphatic), or halo(Ci -4 aliphatic).
  • Optional substituents on the aliphatic group or the phenyl ring of R + are selected from NH 2 , NH(C ⁇ - 4 aliphatic), N(C ⁇ - 4 aliphatic) 2 , halogen, C ⁇ _ 4 aliphatic, OH, 0(C ⁇ -4 aliphatic), N0 2 , CN, C0 2 H, C0 2 (C 1-4 aliphatic), O(halo C 1 - 4 aliphatic), or halo(C ⁇ -4 aliphatic).
  • alkylidene chain refers to a straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation and has two points of attachment to the rest of the molecule.
  • a combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays .
  • the present invention relates to a compound of formula I :
  • the present invention relates to a compound of formula I :
  • R 1 and Ar 1 are as defined above, provided that: R 1 is other than CN.
  • Preferred Ar 1 groups of formula I are optionally substituted rings selected from:
  • Ar 1 groups of formula I are rings selected from: (a) a phenyl, indanyl, or naphthyl ring;
  • Ar 1 is substituted by one to four substituents selected from the group consisting of: (a) one group selected from QR, Ar 2 , or QAr 2 ; and (b) up to four R 2 groups.
  • Ar 1 rings are selected from substituted phenyl, indanyl, naphthyl, pyrimidinyl , or pyridyl .
  • Preferred R 2 substituents on Ar 1 are halogen, CN, C0 2 R, R, N0 2 , OR, haloalkyl, S0 2 N(R) 2 , or N(R) 2 .
  • R 2 substituents on Ar 1 are fluoro, iodo, chloro, bromo, C0 2 CH 3 , methyl, ethyl, t-butyl, NH 2 , NHMe, N(Me) 2 , OH, 0CH 3 , OCH2CH 3 , CF 3 , S0 2 NH 2 , or S0 2 NHMe.
  • Other preferred compounds include those where two R 2 are taken together to form a methylenedioxy or an ethylenedioxy substituent.
  • Preferred QR or QAr 2 substituents on Ar 1 of formula I are those wherein Q is a C ⁇ - 4 alkylidene chain wherein one or two methylene units of Q are optionally replaced by 0, NR, NRCO, NRC0 2 , NRS0 2 , or CONR, wherein each R is hydrogen or an optionally substituted C ⁇ _ 4 aliphatic group and wherein Ar 2 is a 3-6 membered carbocyclic ring or an optionally substituted phenyl, 5-6 membered heterocyclic, or heteroaryl ring having one to two heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • the Ar 2 group of the QAr 2 moiety of formula I is optionally substituted with R, OR, N(R) 2 , S0 2 R, halogen, N0 2 , CN, SR, S0 2 N(R) , C0 2 R, C(0)R, or oxo .
  • More preferred QAr 2 groups of formula I are selected from 0(CH 2 ) 3 pyrrolidin-l-yl, O (CH 2 ) 2 orpholin-4-yl, 0(CH 2 ) 3 (4- hydroxyethylpiperazin-1-yl) , 0 (CH 2 ) 3 piperazin-l-yl, 0(CH 2 ) 3 (4-hydroxymethylpiperidin-l-yl) , 0(CH 2 ) 3 (4- hydroxypiperidin-1-yl) , NHC0CH 2 pyridin-2-yl, NHC0CH 2 (2- aminothiazol-4-yl) , NHCOCH 2 cyclopropyl,
  • NHCO(CH 2 ) 2 (piperazin-2,5-dione-3-yl) , NHCOpyrrolidin-1-yl , NHCOmorpholin-4 -yl , NHC0 2 CH 2 tetrahydrofuran-2 -yl , NHC0 2 tetrahydrofuran-2-yl, NHC0 2 tetrahydropyran-4-yl, NHC0 2 CH 2 tetrahydropyran-2-yl, Ophenyl, OCH 2 (cyclohexyl) , OCH 2 phenyl, 0CH 2 (3 -CN-phenyl ) , OCH 2 (2 -N0 2 -phenyl ) , OCH 2 (3- NH 2 -phenyl ) , OCH 2 (4-C0 2 R-phenyl) , OCH 2 -pyridyl , OCH 2 (mono- , di-, or tri -halogenated phenyl
  • Ar 2 substituents on Ar 1 of formula I are optionally substituted rings selected from:
  • Ar 2 is optionally substituted with 1-2 R 2 groups . More preferred Ar 2 substituents on Ar 1 of formula I are optionally substituted rings selected from phenyl, pyridyl, indolyl, naphthyl, or benzo [1,3] dioxolyl . Preferred R 2 groups, when present, on the Ar 2 substituent on Ar 1 of formula I are selected from R, halogen, N0 2 , CN, OR, SR, N(R) 2 , C(0)R, S0 2 N(R) 2 , or S0 2 R.
  • R 2 groups when present, on the Ar 2 substituent on Ar 1 of formula I are selected from methyl, ethyl, t-butyl, fluoro, chloro, bromo, CF 3 , OMe, OEt, CN, S0 2 Me, S0 2 NH 2 , NH 2 , NHMe, N(Me) 2 , SMe, SEt, OH, C(0)Me, N0 2 , or CH 2 OH.
  • Preferred Ar 1 groups of formula la are those described above for formula I.
  • R 2 is as defined above.
  • Preferred R 2 groups of formula II are those defined above for formula I and include those where two R 2 are taken together to form a methylenedioxy or an ethylenedioxy substituent.
  • a preferred embodiment of this invention relates to a compound of formula Ila or Ila' :
  • Preferred R 2 groups of formula Ila or Ila' are those described above for compounds of formula I.
  • Another preferred embodiment relates to a compound of formula III:
  • R 1 , R 2 , and QAr 2 are as defined above.
  • R 2 and QAr 2 groups of formula III are those described above for formula I .
  • R 1 groups of formula III are selected from hydrogen, N(R) 2 , SR, OR, or TR. More preferred R 1 groups are selected from OH, OCH 3 , CH 2 OH, CH 2 OCH 3 , CH 2 NH 2 , or CH 2 NHCH 3 .
  • R 2 and Ar 2 groups of formula IV are those described above for compounds of formula I.
  • Reagents and conditions (a) DMF-DMA, THF, 12-18 hours, room temperature; (b) H 2 NCN, 4N HCI in dioxane, 12-18 hours, 120°C; (c) Ethanol, reflux, 12-18 hours.
  • step (a) a solution of 2-acetyl thiazole
  • step (b) To prepare intermediate 4 from aniline 3_ in step (b) , a mixture of 3_ and cyanamide in HCI (4N in dioxane) is heated at 120°C overnight. After cooling to room temperature, aqueous work-up affords the desired guanidine compound 4.
  • a wide variety of aryl guanidines may be prepared at step (b) and, thus, be used to prepare compounds of formula I with a wide variety of Ar 1 rings .
  • step (c) guanidine 4_ is combined with enaminone 2 in ethanol in a sealed tube. The resulting mixture is heated at reflux overnight then concentrated and the crude product purified by column chromatography to afford the desired pyrimidine compound 5. The details of the conditions used for producing these compounds are set forth in the Examples.
  • the activity of a compound utilized in this invention as an inhibitor of GSK3 , Aurora2 , or Syk protein kinase may be assayed in vi tro, in vivo or in a cell line according to methods known in the art and by the methods set forth in the Examples below.
  • Jn vitro assays include assays that determine inhibition of either the phosphorylation activity or ATPase activity of activated GSK3 , Aurora2 , or Syk protein kinase. Alternate in vitro assays quantitate the ability of the inhibitor to bind to GSK3 , Aurora2 , or Syk protein kinase.
  • Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/GSK3 , inhibitor/Aurora2 , or inhibitor/Syk complex and determining the amount of radiolabel bound.
  • inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with GSK3, Aurora2 , or Syk protein kinase bound to known radioligands .
  • Detailed conditions for assaying a compound utilized in this invention as an inhibitor of GSK3 , Aurora2 , or Syk protein kinase are set forth in the Examples below.
  • the present invention provides a composition, or pharmaceutically acceptable composition, comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • the amount of compound in the compositions of this invention is such that is effective to detectably inhibit a protein kinase, particularly GSK3 , Aurora2 , or Syk protein kinase, in a biological sample or in a patient.
  • the composition of this invention is formulated for administration to a patient in need of such composition.
  • the composition of this invention is formulated for oral administration to a patient.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated.
  • Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates , waxes, polyethylene-polyoxypropylene-
  • detectably inhibit means a measurable change in GSK3 , Aurora2 , or Syk protein kinase activity between a sample comprising said composition and a GSK3 , Aurora2 , or Syk protein kinase and an equivalent sample comprising GSK3 , Aurora2, or Syk protein kinase in the absence of said composition.
  • a “pharmaceutically acceptable derivative” means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of a GSK3 , Aurora2, or Syk protein kinase.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pe
  • Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N + (C ⁇ - 4 alkyl) 4 salts.
  • alkali metal e.g., sodium and potassium
  • alkaline earth metal e.g., magnesium
  • ammonium e.g., sodium and potassium
  • N + (C ⁇ - 4 alkyl) 4 salts e.g., sodium and potassium
  • alkaline earth metal e.g., magnesium
  • ammonium e.g., sodium and potassium
  • N + (C ⁇ - 4 alkyl) 4 salts e.g., sodium and potassium
  • ammonium e.g., sodium and potassium
  • N + (C ⁇ - 4 alkyl) 4 salts e.g., sodium and potassium
  • ammonium e.g., sodium and potassium
  • N + (C ⁇ - 4 alkyl) 4 salts
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal , intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol .
  • a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1, 3-butanediol .
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides .
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • the pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non- irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
  • the pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs .
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • the pharmaceutically acceptable compositions of this invention are formulated for oral administration.
  • the amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration.
  • the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.
  • additional therapeutic agents which are normally administered to treat or prevent that condition, may also be present in the compositions of this invention.
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition are known as "appropriate for the disease, or condition, being treated".
  • other anti-diabetic agents may be combined with the compounds of this invention to treat diabetes.
  • agents include, without limitation, insulin in injectable or inhalation form, insulin analogues, glitazones, sulfonyl ureas, alpha glucosidase inhibitors, biguanides, and insulin sensitizers.
  • agents the inhibitors of this invention may also be combined with include, without limitation: chemotherapeutic agents such as GleevecTM, adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum derivatives; treatments for Alzheimer's Disease such as Aricept ⁇ and Excelon"; treatments for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl , and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex and Rebif ), Copaxone , and mitoxantrone; treatments for asthma such as albuterol and Singulair * ; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and halope
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • the invention relates to a method of inhibiting GSK3 protein kinase activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
  • the invention relates to a method of inhibiting Aurora2 protein kinase activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
  • the invention relates to a method of inhibiting Syk protein kinase activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • the invention provides a method for treating or lessening the severity of a GSK3 -mediated disease or condition in a patient comprising the step of administering to said patient a composition according to the present invention.
  • GSK3 -mediated disease or "GSK3 - mediated condition”
  • Such conditions include, without limitation, diabetes, neurodegenerative disorders, Alzheimer's disease, Huntington' s,
  • the invention provides a method for treating or lessening the severity of an Aurora2 -mediated disease or condition in a patient comprising the step of administering to said patient a composition according to the present invention.
  • Aurora2 -mediated disease or “Aurora2 -mediated condition”, as used herein, means any disease or other deleterious condition in which Aurora2 protein kinase is known to play a role. Such conditions include, without limitation, cancers such as colon and breast cancer.
  • the invention provides a method for treating or lessening the severity of a Syk-mediated disease or condition in a patient comprising the step of administering to said patient a composition according to the present invention.
  • Syk-mediated disease or "Syk- mediated condition”, as used herein, means any disease or other deleterious condition in which Syk protein kinase is known to play a role. Such conditions include, without limitation, allergic disorders, especially asthma .
  • the methods of this invention that utilize compositions that do not contain an additional therapeutic agent comprise the additional step of separately administering to said patient an additional therapeutic agent. When these additional therapeutic agents are administered separately they may be administered to the patient prior to, sequentially with or following administration of the compositions of this invention.
  • Example 4 We have prepared other compounds of formula I by methods substantially similar to those described in the above Examples 1-3 and those illustrated in Scheme I.
  • the characterization data for these compounds is summarized in Table 3 below and includes LC/MS (M+l observed), HPLC, and X HNMR data.
  • R t (min) refers to the retention time, in minutes, associated with the compound using the following HPLC method.
  • the R was determined using a Waters ODS-AQ (2 x 50mm) column at ambient temperature with a gradient of 10 ⁇ 90% CH 3 CN in water over 5 minutes and with the absorbance detected as an average of 190-380 nM @ 4 nM increments .
  • Y designates that X HNMR data was obtained and found to be consistant with the assigned structure .
  • Compound numbers correspond to the compound numbers listed in Table 1.
  • Example 5 GSK-3 Inhibition Assay Compounds were screened for their ability to inhibit GSK3- ⁇ (AA 1-420) activity using a standard coupled enzyme system (Fox et al . (1998) Protein Sci . 7, 2249) . Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl 2 , 25 mM NaCl , 300 ⁇ M NADH, 1 mM DTT and 1.5% DMSO . Final substrate concentrations in the assay were 10 ⁇ M ATP (Sigma Chemicals, St Louis, MO) and 300 ⁇ M peptide (HSSPHQS (P0 3 H 2 ) EDEEE, American Peptide, Sunnyvale, CA) .
  • HEPES pH 7.5
  • 10 mM MgCl 2 25 mM NaCl
  • 300 ⁇ M NADH 1 mM DTT and 1.5% DMSO
  • Final substrate concentrations in the assay were 10 ⁇ M ATP
  • Reactions were carried out at 30 °C and 60 nM GSK-3 ⁇ . Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate , 300 ⁇ M NADH, 30 ⁇ g/ml pyruvate kinase and 10 ⁇ g/ml lactate dehydrogenase .
  • An assay stock buffer solution was prepared containing all of the reagents listed above with the exception of ATP and the test compound of interest. 59 ⁇ l of the test reaction was placed in a 96 well - diameter plate (Corning, Corning, NY) then treated with 1 ⁇ l of a 2 mM DMSO stock containing the test compound (final compound concentration 30 ⁇ M) .
  • Example 6 Aurora2 Inhibition Assay Compounds are screened in the following manner for their ability to inhibit Aurora2 using a standard coupled enzyme assay (Fox et al (1998) Protein Sci 7, 2249).
  • a standard coupled enzyme assay Frax et al (1998) Protein Sci 7, 2249).
  • the resulting mixture is incubated at 30 °C for 10 minutes.
  • the reaction was initiated by the addition of 10 ⁇ L of Aurora2 stock solution to give a final concentration of 70 nM in the assay.
  • the rates of reaction are obtained by monitoring absorbance at 340 nm over a 5 minute read time at 30 °C using a BioRad Ultramark plate reader (Hercules, CA) .
  • the IC 50 values are determined from the rate data as a function of inhibitor concentration.
  • Table 5 shows the results of the activity of selected compounds of this invention in the Aurora2 inhibition assay.
  • the compound numbers correspond to the compound numbers in Table 1.
  • Compounds having an IC 50 less than 0.5 micromolar ( ⁇ M) are rated “A”
  • compounds having an IC 50 between 0.5 and 2 ⁇ M are rated “B”
  • compounds having an IC 50 greater than 2 ⁇ M are rated “C” .
  • Example 7 Syk Inhibition Assay Compounds were screened for their ability to inhibit Syk using a standard coupled enzyme assay (Fox et al (1998) Protein Sci 7, 2249) . Reactions were carried out in 100 mM HEPES pH 7.5, 10 mM MgCl2, 25 mM NaCl, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 200 ⁇ M ATP (Sigma chemical Co.) and 4 ⁇ M poly Gly-Tyr peptide (Sigma Chemical Co.) . Assays were carried out at 30 °C and 200 nM Syk.
  • Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 ⁇ M NADH, 30 ⁇ g/ml pyruvate kinase and 10 ⁇ g/ml lactate dehydrogenase .
  • An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of Syk, DTT and the test compound of interest. 56 ⁇ l of the test reaction was placed in a 96 well plate followed by the addition of 1 ⁇ l of 2 mM DMSO stock containing the test compound (final compound concentration 30 ⁇ M) .
  • the plate was pre-incubated for -10 minutes at 30 °C and the reaction initiated by the addition of 10 ⁇ l of enzyme (final concentration 25 nM) . Rates of reaction were obtained using a BioRad Ultramark plate reader (Hercules, CA) over a 5 minute read time at 30 "C. Compounds showing >50 % inhibition versus standard wells containing DMSO, but no compound, were titrated and IC50's determined using a similar protocol.
  • Table 6 shows the results of the activity of selected compounds of this invention in the Syk inhibition assay.
  • the compound numbers correspond to the compound numbers in Table 1.
  • Compounds having an IC 50 less than 0.5 micromolar ( ⁇ M) are rated “A”
  • compounds having an IC 50 between 0.5 and 2 ⁇ M are rated “B”
  • compounds having an IC 50 greater than 2 ⁇ M are rated “C” .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a compound of formula I: or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK3, Aurora2, and Syk mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatement of various protein kinase mediated disorders.

Description

THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE
CROSS REFERENCE TO RELATED APPLICATION This application claims priority to US Provisional Patent Application 60/295,158 filed June 1, 2001, the contents of which are incorporated herein by reference.
FIELD OF THE INVENTION The present invention relates to compounds that are protein kinase inhibitors, pharmaceutically acceptable compositions comprising said compounds, and methods of use thereof. More particularly, the compounds are inhibitors of GSK-3, Aurora2 , and Syk protein kinases and are useful for treating, or lessening the severity of, a variety of diseases and conditions, such as diabetes, Alzheimer's disease, stroke, proliferative disorders, and asthma.
BACKGROUND OF THE INVENTION
The search for new therapeutic agents has been greatly aided in recent years by better understanding of the structure of enzymes and other biomolecules associated with target diseases. One important class of enzymes that has been the subject of extensive study is the protein kinases.
Protein kinases mediate intracellular signal transduction. They do this by affecting a phosphoryl transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway. There are a number of kinases and pathways through which extracellular and other stimuli cause a variety of cellular responses to occur inside the cell. Examples of such stimuli include environmental and chemical stress signals (e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H202) , cytokines (e.g. interleukin-1 (IL-1) and tumor necrosis factor α (TNF- α) ) , and growth factors (e.g. granulocyte macrophage- colony-stimulating factor (GM-CSF) , and fibroblast growth factor (FGF) . An extracellular stimulus may effect one or more cellular responses related to cell growth, migration, differentiation, secretion of hormones, activation of transcription factors, muscle contraction, glucose metabolism, control of protein synthesis and regulation of cell cycle.
Many diseases and conditions are associated with abnormal cellular responses triggered by protein kinase-mediated events. These diseases include autoimmune diseases, inflammatory diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease or hormone-related diseases. Accordingly, there has been a substantial effort in medicinal chemistry to find protein kinase inhibitors that are effective as therapeutic agents.
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase comprised of α and β isoforms that are each encoded by distinct genes [Coghlan et al . , Chemistry & Biology, 7, 793-803 (2000); Kim and Kimmel, Curr. Opinion Genetics Dev. , 10, 508-514 (2000)]. GSK-3 has been implicated in various diseases including diabetes, Alzheimer's disease, CNS disorders such as manic depressive disorder and neurodegenerative diseases, and cardio yocete hypertrophy [WO 99/65897; WO 00/38675; and Haq et al . , J. Cell Biol . (2000) 151, 117]. These diseases may be caused by, or result in, the abnormal operation of certain cell signaling pathways in which GSK-3 plays a role. GSK-3 has been found to phosphorylate and modulate the activity of a number of regulatory proteins. These include glycogen synthase which is the rate limiting enzyme necessary for glycogen synthesis, the microtubule associated protein Tau, the gene transcription factor β-catenin, the translation initiation factor elF2B, as well as ATP citrate lyase, axin, heat shock factor-1, c-Jun, c-Myc, c-Myb, CREB, and CEPBα. These diverse targets implicate GSK-3 in many aspects of cellular metabolism, proliferation, differentiation and development.
In a GSK-3 mediated pathway that is relevant for the treatment of type II diabetes, insulin-induced signaling leads to cellular glucose uptake and glycogen synthesis. Along this pathway, GSK-3 is a negative regulator of the insulin-induced signal. Normally, the presence of insulin causes inhibition of GSK-3 mediated phosphorylation and deactivation of glycogen synthase. The inhibition of GSK-3 leads to increased glycogen synthesis and glucose uptake [Klein et al . , PNAS, 93, 8455-9 (1996); Cross et al . , Biochem . J. , 303, 21-26 (1994); Cohen, Biochem . Soc . Trans . , 21, 555-567 (1993); Massillon et al . , Biochem J. 299, 123-128 (1994)]. However, in a diabetic patient where the insulin response is impaired, glycogen synthesis and glucose uptake fail to increase despite the presence of relatively high blood levels of insulin. This leads to abnormally high blood levels of glucose with acute and long term effects that may ultimately result in cardiovascular disease, renal failure and blindness. In such patients, the normal insulin-induced inhibition of GSK-3 fails to occur. It has also been reported that in patients with type II diabetes, GSK-3 is overexpressed [WO 00/38675] .
Therapeutic inhibitors of GSK-3 are therefore potentially useful for treating diabetic patients suffering from an impaired response to insulin.
GSK-3 activity has also been associated with Alzheimer's disease. This disease is characterized by the well-known β-amyloid peptide and the formation of intracellular neurofibrillary tangles. The neurofibrillary tangles contain hyperphosphorylated Tau protein where Tau is phosphorylated on abnormal sites. GSK-3 has been shown to phosphorylate these abnormal sites in cell and animal models. Furthermore, inhibition of GSK-3 has been shown to prevent hyperphosphorylation of Tau in cells [Lovestone et al . , Current Biology 4, 1077-86 (1994); Brownlees et al . , Neuroreport 8, 3251-55 (1997)]. Therefore, it is believed that GSK-3 activity may promote generation of the neurofibrillary tangles and the progression of Alzheimer's disease.
Another substrate of GSK-3 is β-catenin which is degradated after phosphorylation by GSK-3. Reduced levels of β-catenin have been reported in schizophrenic patients and have also been associated with other diseases related to increase in neuronal cell death [Zhong et al . , Nature, 395, 698-702 (1998); Takashima et al., PNAS, 90, 7789-93 (1993); Pei et al . , J. Neuropathol . Exp, 56, 70-78 (1997)].
Aurora-2 is a serine/threonine protein kinase that has been implicated in human cancer, such as colon, breast and other solid tumors. This kinase is involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-2 plays a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities. In human colon cancer tissue, the aurora-2 protein has been found to be overexpressed [Bischoff et al . , EMBO J. , 17, 3052-3065 (1998); Schumacher et al . , J. Cell Biol . , 143, 1635-1646 (1998); Kimura et al . , J". Biol . Chem . , 272, 13766-13771 (1997) ] .
Syk is a tyrosine kinase that plays a critical role in FcεRI mediated mast cell degranulation and eosiniphil activation. Accordingly, Syk kinase is implicated in various allergic disorders, in particular asthma.
It has been shown that Syk binds to the phosphorylated gamma chain of the FcεRI receptor via N- terminal SH2 domains and is essential for downstream signaling [Taylor et al, Mol Cell Biol 1995; 15:4149]. Inhibition of eosinophil apoptosis has been proposed as key mechanisms for the development of blood and tissue eosinophilia in asthma. IL-5 and GM-CSF are upregulated in asthma and are proposed to cause blood and tissue eosinophilia by inhibition of eosinophil apoptosis. Inhibition of eosinophil apoptosis has been proposed as a key mechanism for the development of blood and tissue eosinophilia in asthma. It has been reported that Syk kinase is required for the prevention of eosinophil apoptosis by cytokines (using antisense) [Yousefi et al, J Exp Med 1996 ; 183 : 1407] . The role of Syk in FcγR dependent and independent response in bone marrow derived macrophages has been determined by using irradiated mouse chimeras reconstituted with fetal liver cells from Syk -/- embryos. Syk deficient macrophages were defective in phagocytosis induced by FcγR but showed normal phagocytosis in response to complement [Kiefer et al, Mol Cell Biol 1998; 18:4209]. It has also been reported that aerosolized Syk antisense suppresses Syk expression and mediator release from macrophages [Stenton et al, J Immunology 2000; 164: 3790].
Considering the lack of currently available treatment options for the majority of the conditions associated with protein kinases, especially GSK-3, Aurora-2, and Syk, there is still a great need for new therapeutic agents that inhibit these protein targets.
SUMMARY OF THE INVENTION The present invention addresses this need by providing a compound of formula I:
Figure imgf000007_0001
I or a pharmaceutically acceptable derivative thereof, wherein R1 and Ar1 are as defined below. The present invention also provides a pharmaceutically acceptable composition comprising a compound of formula I .
The compounds and pharmaceutically acceptable compositions of the present invention are useful as inhibitors of GSK-3, Aurora-2, and Syk protein kinases. Thus, they are also useful in methods for treating or lessening the severity of a variety of disorders, such as allergic diseases, proliferative disorders, cancer, neurodegenerative disorders, and diabetes.
DESCRIPTION OF THE INVENTION The present invention relates to a compound of formula I :
Figure imgf000008_0001
I or a pharmaceutically acceptable derivative thereof, wherein:
R1 is selected from R, halogen, CN, N02, or TR; T is an optionally substituted Cι-C4 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by O, N(R), C(O), S, SO, or S02; each R is independently selected from hydrogen or an optionally substituted Cι-6 aliphatic group, wherein: two R bound to the same nitrogen atom are optionally taken together with the nitrogen to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms, in addition to the nitrogen bound thereto, independently selected from nitrogen, oxygen, or sulfur; Ar1 is an optionally substituted ring selected from: (a) a 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially unsaturated, or aryl ring;
(b) a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
Ar1 is optionally substituted by one to four substituents selected from the group consisting of:
(a) one group selected from QR, Ar2, or QAr2; and
(b) up to four R2 groups; each Q is indpendently selected from a valence bond or an optionally substituted C1-6 alkylidene chain, wherein: one or two non-adjacent methylene units of Q are optionally and independently replaced by -O- , -S-,
-NR-, -C(O)-, -C02-, -C(0)NR-, -OC(0)NR-, -C(0)C(0)-, -C(0)C(0)-, -NRC(O)-, NRC02-, -NRC(0)NR-, -S(0)-, -S02-, -NRS02-, -S02NR-, or -NRSO2NR- ; each Ar2 is an optionally substituted ring independently selected from:
(a) a 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially unsaturated, or aryl ring; (b) a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or (c) a 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein: Ar2 is optionally substituted by one to four R2 groups ; and each R2 is independently selected from R, halogen, N02, CN, OR, SR, N(R)2, NRCOR, NRCON(R)2, NRC02R, C(0)R, C02R, C0N(R)2, 0C(0)N(R)2, SOR, S02R, S02N(R)2, NRS02R, NRS02N(R)2, C(0)C(0)R, or C (0) CH2C (O) R; wherein: two R2 on adjacent positions on Ar1 or Ar2 are optionally taken together to form a saturated, partially unsaturated, or fully unsaturated 4-6 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
As used herein, the following definitions shall apply unless otherwise indicated.
The phrase "optionally substituted" is used interchangeably with the phrase "substituted or unsubstituted." Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other. The term "aliphatic" or "aliphatic group" as used herein means a straight-chain or branched Cι-C8 hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic C3-C8 hydrocarbon or bicyclic C8-Cι2 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle" or "cycloalkyl"), that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members. For example, suitable aliphatic groups include, but are not limited to, linear or branched or alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl) alkyl, (cycloalkenyl) alkyl or (cycloalkyl) alkenyl.
The terms "alkyl", "alkoxy", "hydroxyalkyl" , "alkoxyalkyl" , and "alkoxycarbonyl", used alone or as part of a larger moiety include both straight and branched chains containing one to twelve carbon atoms. The terms "alkenyl" and "alkynyl" used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve carbon atoms.
The term "heteroatom" means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. Also the term "nitrogen" includes a substitutable nitrogen of a heterocyclic ring. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3 , 4-dihydro-2H-pyrrolyl) , NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl) .
The term "aryl" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy" , or "aryloxyalkyl" , refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the term "aryl ring". The term
"aryl" also refers to heteroaryl ring systems as defined hereinbelow. The term "heterocycle" , "heterocyclyl" , or "heterocyclic" as used herein means non-aromatic, monocyclic, bicyclic or tricyclic ring systems having five to fourteen ring members in which one or more ring members is a heteroatom, wherein each ring in the system contains 3 to 7 ring members.
The term "heteroaryl" , used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy" , refers to monocyclic, bicyclic and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term "heteroaryl" may be used interchangeably with the term "heteroaryl ring" or the term "heteroaromatic" .
An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Suitable substituents on the unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group are selected from halogen, -R°, -0R°, -SR°, 1, 2-methylene-dioxy, 1,2- ethylenedioxy, phenyl (Ph) optionally substituted with R°, -O(Ph) optionally substituted with R°, -CH2(Ph) optionally substituted with R°, -CH2CH2 (Ph) , optionally substituted with R°, -N02, -CN, -N(R°)2, -NR°C(0)R°, -NR°C (O) N (R°) 2, -NR°C02R°, -NR°NR°C(0)R°, -NR°NR°C (O) N (R°) 2, -NR°NR°C02R°, -C(0)C(0)R°, -C(0)CH2C(0)R°, -C02R°, -C(0)R°, -C(0)N(R°)2, -0C(0)N(R°)2, -S(0)2R°, -S02N(R°)2, -S(0)R°, -NR°S02N (R°) 2,
-NR°S02R° , -C ( =S) N (R°) 2 , -C ( =NH) -N (R°) 2 , or - (CH2 ) yNHC (0) R° , wherein each R° is independently selected from hydrogen, optionally substituted Cι_6 aliphatic, an unsubstituted 5-6 membered heteroaryl or heterocyclic ring, phenyl, -O(Ph), or -CH2(Ph). Optional substituents on the aliphatic group of R° are selected from NH2, NH(C1-4 aliphatic), N(Cι_4 aliphatic)2, halogen, Ci-4 aliphatic, OH, 0(Ci-4 aliphatic), N02, CN, C02H, C02 (Cι-4 aliphatic), O(halo Cι-4 aliphatic) , or halo Cι_4 aliphatic.
An aliphatic group or a non-aromatic heterocyclic ring may contain one or more substituents. Suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring are selected from those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: =0, =S, =NNHR*, =NN(R*)2, =NNHC(0)R*, =NNHC02 (alkyl) , =NNHS02 (alkyl) , or =NR*, where each R* is independently selected from hydrogen or an optionally substituted Cι-6 aliphatic. Optional substituents on the aliphatic group of R* are selected from NH2, NH(Cι-4 aliphatic), N(Cι_ aliphatic) 2 halogen, Cι-4 aliphatic, OH, 0(Cι_4 aliphatic), N02, CN, C02H, C02(Ci-4 aliphatic), 0(halo C1-4 aliphatic), or halo(Ci-4 aliphatic).
Optional substituents on the nitrogen of a non- aromatic heterocyclic ring are selected from -R+, -N(R+)2, -C(0)R+, -C02R\ -C(0)C(0)R+, -C (O) CH2C (O) R+, -S02R+, -S02N(R+)2, -C(=S)N(R+)2, -C (=NH) -N (R+) 2, or -NR+S02R+; wherein R+ is hydrogen, an optionally substituted Cι-6 aliphatic, optionally substituted phenyl, optionally substituted -O(Ph), optionally substituted -CH2(Ph), optionally substituted -CH2CH2(Ph), or an unsubstituted 5- 6 membered heteroaryl or heterocyclic ring. Optional substituents on the aliphatic group or the phenyl ring of R+ are selected from NH2, NH(Cι-4 aliphatic), N(Cι-4 aliphatic) 2, halogen, Cι_4 aliphatic, OH, 0(Cι-4 aliphatic), N02, CN, C02H, C02(C1-4 aliphatic), O(halo C1-4 aliphatic), or halo(Cι-4 aliphatic).
The term "alkylidene chain" refers to a straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation and has two points of attachment to the rest of the molecule.
A combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound. A stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention.
Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays . According to one embodiment , the present invention relates to a compound of formula I :
Figure imgf000015_0001
I or a pharmaceutically acceptable derivative thereof, wherein R1 and Ar1 are as defined above, provided that: when Ar1 is phenyl with two R2 substituents, then the two R2 are not simultaneously OR in the meta and para positions of Ar1. According to another embodiment, the present invention relates to a compound of formula I :
Figure imgf000015_0002
I or a pharmaceutically acceptable derivative thereof, wherein R1 and Ar1 are as defined above, provided that: R1 is other than CN.
Preferred Ar1 groups of formula I are optionally substituted rings selected from:
(a) a phenyl, indanyl, or naphthyl ring; (b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or (c) a 5-6 membered monocyclic or 9-10 membered bicyclic heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, nitrogen, or sulfur. More preferred Ar1 groups of formula I are rings selected from: (a) a phenyl, indanyl, or naphthyl ring;
(b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic heteroaryl ring having 1-2 nitrogens, wherein:
Ar1 is substituted by one to four substituents selected from the group consisting of: (a) one group selected from QR, Ar2, or QAr2; and (b) up to four R2 groups.
Most preferred Ar1 rings are selected from substituted phenyl, indanyl, naphthyl, pyrimidinyl , or pyridyl . Preferred R2 substituents on Ar1 are halogen, CN, C02R, R, N02, OR, haloalkyl, S02N(R)2, or N(R)2. More preferred R2 substituents on Ar1 are fluoro, iodo, chloro, bromo, C02CH3, methyl, ethyl, t-butyl, NH2, NHMe, N(Me)2, OH, 0CH3, OCH2CH3, CF3, S02NH2, or S02NHMe. Other preferred compounds include those where two R2 are taken together to form a methylenedioxy or an ethylenedioxy substituent. Preferred QR or QAr2 substituents on Ar1 of formula I are those wherein Q is a Cι-4 alkylidene chain wherein one or two methylene units of Q are optionally replaced by 0, NR, NRCO, NRC02, NRS02, or CONR, wherein each R is hydrogen or an optionally substituted Cι_4 aliphatic group and wherein Ar2 is a 3-6 membered carbocyclic ring or an optionally substituted phenyl, 5-6 membered heterocyclic, or heteroaryl ring having one to two heteroatoms independently selected from nitrogen, oxygen, or sulfur.
The Ar2 group of the QAr2 moiety of formula I is optionally substituted with R, OR, N(R)2, S02R, halogen, N02, CN, SR, S02N(R) , C02R, C(0)R, or oxo . More preferred QAr2 groups of formula I are selected from 0(CH2)3pyrrolidin-l-yl, O (CH2) 2 orpholin-4-yl, 0(CH2)3(4- hydroxyethylpiperazin-1-yl) , 0 (CH2) 3piperazin-l-yl, 0(CH2)3 (4-hydroxymethylpiperidin-l-yl) , 0(CH2)3(4- hydroxypiperidin-1-yl) , NHC0CH2pyridin-2-yl, NHC0CH2(2- aminothiazol-4-yl) , NHCOCH2cyclopropyl,
NHCO(CH2)2 (piperazin-2,5-dione-3-yl) , NHCOpyrrolidin-1-yl , NHCOmorpholin-4 -yl , NHC02CH2tetrahydrofuran-2 -yl , NHC02tetrahydrofuran-2-yl, NHC02tetrahydropyran-4-yl, NHC02CH2tetrahydropyran-2-yl, Ophenyl, OCH2 (cyclohexyl) , OCH2phenyl, 0CH2 (3 -CN-phenyl ) , OCH2 (2 -N02-phenyl ) , OCH2(3- NH2-phenyl ) , OCH2 (4-C02R-phenyl) , OCH2-pyridyl , OCH2 (mono- , di-, or tri -halogenated phenyl), OCH2(Cι-C6 aliphatic substituted phenyl) , OCH2CH2-pyrrolyl , OCH2-pyrrolyl, and OCH2 (phenyl substituted with one or two R2)
Preferred Ar2 substituents on Ar1 of formula I are optionally substituted rings selected from:
(a) a phenyl, indanyl, or naphthyl ring;
(b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic or 9-10 membered bicyclic heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, nitrogen, or sulfur, wherein:
Ar2 is optionally substituted with 1-2 R2 groups . More preferred Ar2 substituents on Ar1 of formula I are optionally substituted rings selected from phenyl, pyridyl, indolyl, naphthyl, or benzo [1,3] dioxolyl . Preferred R2 groups, when present, on the Ar2 substituent on Ar1 of formula I are selected from R, halogen, N02, CN, OR, SR, N(R)2, C(0)R, S02N(R)2, or S02R. More preferred R2 groups, when present, on the Ar2 substituent on Ar1 of formula I are selected from methyl, ethyl, t-butyl, fluoro, chloro, bromo, CF3 , OMe, OEt, CN, S02Me, S02NH2, NH2, NHMe, N(Me)2, SMe, SEt, OH, C(0)Me, N02, or CH2OH.
One embodiment of this invention relates to a compound of formula la:
Figure imgf000018_0001
la or a pharmaceutically acceptable derivative thereof, wherein Ar1 is as defined above.
Preferred Ar1 groups of formula la are those described above for formula I.
Another embodiment of this invention relates to a compound of formula II:
Figure imgf000019_0001
II or a pharmaceutically acceptable derivative thereof, wherein R2 is as defined above. Preferred R2 groups of formula II are those defined above for formula I and include those where two R2 are taken together to form a methylenedioxy or an ethylenedioxy substituent.
A preferred embodiment of this invention relates to a compound of formula Ila or Ila' :
Figure imgf000019_0002
Ila Ila' or a pharmaceutically acceptable derivative thereof, wherein QR, QAr2 and R2 are as defined above. Preferred R2 groups of formula Ila or Ila' are those described above for compounds of formula I.
Preferred QR and QAr2 groups of formula Ila or
Ila' are those described above for compounds of formula
I. Another preferred embodiment relates to a compound of formula III:
Figure imgf000020_0001
III or a pharmaceutically acceptable derivative thereof, wherein R1, R2, and QAr2 are as defined above.
Preferred R2 and QAr2 groups of formula III are those described above for formula I .
Preferred R1 groups of formula III are selected from hydrogen, N(R)2, SR, OR, or TR. More preferred R1 groups are selected from OH, OCH3, CH2OH, CH2OCH3, CH2NH2, or CH2NHCH3.
Another preferred embodiment relates to a compound of formula IV:
Figure imgf000020_0002
IV or a pharmaceutically acceptable derivative thereof, wherein R2 and Ar2 are as defined above.
Preferred R2 and Ar2 groups of formula IV are those described above for compounds of formula I.
Exemplary structures of formula I are set forth in Table 1 below. Table 1. Compounds of Formula I
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Exemplary structures of formulae Ila and Ila' are set forth in Table 2 below.
Table 2. Compounds of Formulae Ila and Ila'
Figure imgf000026_0002
IIa-1 IIa-2
Figure imgf000027_0001
IIa-3 IIa-4
Figure imgf000027_0002
a-5 IIa-6
Figure imgf000027_0003
IIa-7 IIa-8
Figure imgf000027_0004
IIa-9 IIa-10
Figure imgf000027_0005
IIa-11 IIa-12
Figure imgf000027_0006
IIa-13 IIa-14
Figure imgf000027_0007
IIa-15 IIa-16
Figure imgf000028_0001
IIa-17 IIa-18
Figure imgf000028_0002
IIa-19 IIa-20
Figure imgf000028_0003
IIa-21 IIa-22
Figure imgf000028_0004
IIa-23 IIa-24
Figure imgf000028_0005
IIa-25 IIa-26
Figure imgf000028_0006
IIa-27 IIa-28
Figure imgf000029_0001
IIa-29 IIa-30
Figure imgf000029_0002
IIa-31 IIa-32
Figure imgf000029_0003
IIa-33 IIa-34
Figure imgf000029_0004
IIa-35 IIa-36
Figure imgf000029_0005
IIa-37 IIa-38
Figure imgf000029_0006
IIa-39 IIa-40
Figure imgf000030_0001
IIa-43 IIa-44
Figure imgf000030_0002
IIa-49 IIa-50
The present compounds may be prepared in general by methods known to those skilled in the art for analogous compounds, as illustrated by the general Scheme I and the synthetic examples shown below. Scheme I
Ar1 NH,
(b)
Figure imgf000031_0001
Reagents and conditions: (a) DMF-DMA, THF, 12-18 hours, room temperature; (b) H2NCN, 4N HCI in dioxane, 12-18 hours, 120°C; (c) Ethanol, reflux, 12-18 hours.
Scheme I above shows a general synthetic route that may be used used for preparing compounds of formula
In step (a) , a solution of 2-acetyl thiazole
(1) in THF is treated with dimethylformamide- dimethylacetal and the resulting mixture stirred at room temperature over night. The reaction mixture is concentrated in vacuo and the concentrate triturated with diethyl ether to afford 2.
To prepare intermediate 4 from aniline 3_ in step (b) , a mixture of 3_ and cyanamide in HCI (4N in dioxane) is heated at 120°C overnight. After cooling to room temperature, aqueous work-up affords the desired guanidine compound 4. One of skill in the art would recognize that a wide variety of aryl guanidines may be prepared at step (b) and, thus, be used to prepare compounds of formula I with a wide variety of Ar1 rings . In step (c) , guanidine 4_ is combined with enaminone 2 in ethanol in a sealed tube. The resulting mixture is heated at reflux overnight then concentrated and the crude product purified by column chromatography to afford the desired pyrimidine compound 5. The details of the conditions used for producing these compounds are set forth in the Examples.
The activity of a compound utilized in this invention as an inhibitor of GSK3 , Aurora2 , or Syk protein kinase may be assayed in vi tro, in vivo or in a cell line according to methods known in the art and by the methods set forth in the Examples below. Jn vitro assays include assays that determine inhibition of either the phosphorylation activity or ATPase activity of activated GSK3 , Aurora2 , or Syk protein kinase. Alternate in vitro assays quantitate the ability of the inhibitor to bind to GSK3 , Aurora2 , or Syk protein kinase. Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/GSK3 , inhibitor/Aurora2 , or inhibitor/Syk complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with GSK3, Aurora2 , or Syk protein kinase bound to known radioligands . Detailed conditions for assaying a compound utilized in this invention as an inhibitor of GSK3 , Aurora2 , or Syk protein kinase are set forth in the Examples below. According to another embodiment, the present invention provides a composition, or pharmaceutically acceptable composition, comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in the compositions of this invention is such that is effective to detectably inhibit a protein kinase, particularly GSK3 , Aurora2 , or Syk protein kinase, in a biological sample or in a patient. Preferably the composition of this invention is formulated for administration to a patient in need of such composition. Most preferably, the composition of this invention is formulated for oral administration to a patient.
The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.
The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates , waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat .
The term "detectably inhibit", as used herein means a measurable change in GSK3 , Aurora2 , or Syk protein kinase activity between a sample comprising said composition and a GSK3 , Aurora2 , or Syk protein kinase and an equivalent sample comprising GSK3 , Aurora2, or Syk protein kinase in the absence of said composition. A "pharmaceutically acceptable derivative" means any non-toxic salt, ester, salt of an ester or other derivative of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. As used herein, the term "inhibitorily active metabolite or residue thereof" means that a metabolite or residue thereof is also an inhibitor of a GSK3 , Aurora2, or Syk protein kinase.
Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate . Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N+(Cι-4 alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal , intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol . Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.
For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides . Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
The pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
Alternatively, the pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non- irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols. The pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs .
Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
For topical applications, the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
For ophthalmic use, the pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
The pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
Most preferably, the pharmaceutically acceptable compositions of this invention are formulated for oral administration. The amount of the compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions. It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition. Depending upon the particular condition, or disease, to be treated or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, may also be present in the compositions of this invention. As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated". For example, in the treatment of diabetes other anti-diabetic agents may be combined with the compounds of this invention to treat diabetes. These agents include, without limitation, insulin in injectable or inhalation form, insulin analogues, glitazones, sulfonyl ureas, alpha glucosidase inhibitors, biguanides, and insulin sensitizers. Other examples of agents the inhibitors of this invention may also be combined with include, without limitation: chemotherapeutic agents such as Gleevec™, adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum derivatives; treatments for Alzheimer's Disease such as Aricept^ and Excelon"; treatments for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl , and amantadine; agents for treating Multiple Sclerosis (MS) such as beta interferon (e.g., Avonex and Rebif ), Copaxone , and mitoxantrone; treatments for asthma such as albuterol and Singulair*; agents for treating schizophrenia such as zyprexa, risperdal, seroquel, and haloperidol; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti- Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti- leukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.
The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
According to another embodiment, the invention relates to a method of inhibiting GSK3 protein kinase activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
According to another embodiment, the invention relates to a method of inhibiting Aurora2 protein kinase activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
According to another embodiment, the invention relates to a method of inhibiting Syk protein kinase activity in a biological sample comprising the step of contacting said biological sample with a compound of this invention, or a composition comprising said compound.
The term "biological sample", as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
Inhibition of GSK3 , Aurora2 , or Syk protein kinase activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ- transplantation, biological specimen storage, and biological assays. According to another embodiment, the invention provides a method for treating or lessening the severity of a GSK3 -mediated disease or condition in a patient comprising the step of administering to said patient a composition according to the present invention. The term "GSK3 -mediated disease" or "GSK3 - mediated condition", as used herein, means any disease or other deleterious condition in which GSK3 protein kinase is known to play a role. Such conditions include, without limitation, diabetes, neurodegenerative disorders, Alzheimer's disease, Huntington' s,
Parkinson's, AIDS associated dementia, amyotrophic lateral sclerosis (A L) , multiple sclerosis (MS) , schizophrenia, stroke, cardiomycete hypertrophy, and baldness . According to another embodiment, the invention provides a method for treating or lessening the severity of an Aurora2 -mediated disease or condition in a patient comprising the step of administering to said patient a composition according to the present invention.
The term "Aurora2 -mediated disease" or "Aurora2 -mediated condition", as used herein, means any disease or other deleterious condition in which Aurora2 protein kinase is known to play a role. Such conditions include, without limitation, cancers such as colon and breast cancer.
According to another embodiment, the invention provides a method for treating or lessening the severity of a Syk-mediated disease or condition in a patient comprising the step of administering to said patient a composition according to the present invention.
The term "Syk-mediated disease" or "Syk- mediated condition", as used herein, means any disease or other deleterious condition in which Syk protein kinase is known to play a role. Such conditions include, without limitation, allergic disorders, especially asthma . In an alternate embodiment, the methods of this invention that utilize compositions that do not contain an additional therapeutic agent, comprise the additional step of separately administering to said patient an additional therapeutic agent. When these additional therapeutic agents are administered separately they may be administered to the patient prior to, sequentially with or following administration of the compositions of this invention.
In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner. EXAMPLES Example 1
Figure imgf000043_0001
2
3-Dimet ylamino-l-thiazol-2-yl-propenone ( 2 ) : To a solution of 2-acetylthiazole (500 mg, 3.93 mmol) in 2 mL of THF was added dimethylformamide-dimethylacetal (1.6 ml, 7.86 mmol) and the resulting solution was stirred at room temperature overnight. The reaction mixture was evaporated and the residue triturated with ethyl acetate and the product isolated by filtration. The filtered solid was washed with diethyl ether and dried to afford 2 (400 mg) as a yellow solid.
Example 2
Figure imgf000043_0002
4 N- (3 -Benzyloxy-phenyl) -guanidine (4): 3-benzyloxy aniline (1 g, 5 mmol) and cyanamide (420 mg, 10 mmol) were dissolved in 4 mL of 4N HCI in dioxane and heated to 120°C overnight. The reaction mixture was cooled to room temperature, quenched with water, and extracted with diethyl ether. The aqueous layer was made basic with 2N NaOH and extracted thrice with dichloromethane. The organic extracts were combined and washed with brine, dried over MgS0 , and concentrated to afford 4 (450 mg) as a light brown solid.
Example 3
Figure imgf000044_0001
1-7 (3 -Benzyloxy-phenyl) - (4-thiazol-2-yl-pyrimidin-2-yl) - amine ( -7) : A solution of 3-benzyloxy guanidine 4 (50 mg, 0.20 mmol) and enaminone 2 (50 mg, 0.27 mmol) in ethanol (3 mL) was heated at reflux in a sealed tube overnight. The reaction mixture was concentrated and the residue purified by column chromatography to afford compound 1-7 (20 mg) . M+l (obs) 347.1. Rt = 4.28 minutes.
Example 4 We have prepared other compounds of formula I by methods substantially similar to those described in the above Examples 1-3 and those illustrated in Scheme I. The characterization data for these compounds is summarized in Table 3 below and includes LC/MS (M+l observed), HPLC, and XHNMR data.
The term "Rt(min)" refers to the retention time, in minutes, associated with the compound using the following HPLC method. The R was determined using a Waters ODS-AQ (2 x 50mm) column at ambient temperature with a gradient of 10→90% CH3CN in water over 5 minutes and with the absorbance detected as an average of 190-380 nM @ 4 nM increments . The term "Y" designates that XHNMR data was obtained and found to be consistant with the assigned structure . Compound numbers correspond to the compound numbers listed in Table 1.
Table 3. Characterization Data for Selected Compounds of Formula I
Figure imgf000045_0001
Figure imgf000046_0001
Example 5 GSK-3 Inhibition Assay Compounds were screened for their ability to inhibit GSK3-β (AA 1-420) activity using a standard coupled enzyme system (Fox et al . (1998) Protein Sci . 7, 2249) . Reactions were carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl2, 25 mM NaCl , 300 μM NADH, 1 mM DTT and 1.5% DMSO . Final substrate concentrations in the assay were 10 μM ATP (Sigma Chemicals, St Louis, MO) and 300 μM peptide (HSSPHQS (P03H2) EDEEE, American Peptide, Sunnyvale, CA) . Reactions were carried out at 30 °C and 60 nM GSK-3β. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate , 300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase . An assay stock buffer solution was prepared containing all of the reagents listed above with the exception of ATP and the test compound of interest. 59 μl of the test reaction was placed in a 96 well - diameter plate (Corning, Corning, NY) then treated with 1 μl of a 2 mM DMSO stock containing the test compound (final compound concentration 30 μM) . The plate was incubated for -10 minutes at 30 °C then the reaction initiated by addition of 7 μl of ATP (final concentration 10 μM) . Rates of reaction were obtained using a Molecular Devices Spectramax plate reader (Sunnyvale, CA) over a 5 minute read time at 30 °C. Compounds showing greater than 50 % inhibition versus standard wells containing DMSO, but no compound, were titrated and Ki values were determined. Table 4 shows the results of the activity of selected compounds of this invention in the GSK3 inhibition assay. The compound numbers correspond to the compound numbers in Table 1. Compounds having a Ki less than 0.1 micromolar (μM) are rated "A" , compounds having a Ki between 0.1 and 1 μM are rated "B" and compounds having a Ki greater than 1 μM are rated "C" .
Table 4. GSK3-β Activity of Selected Compounds
Figure imgf000047_0001
Figure imgf000048_0001
Example 6 Aurora2 Inhibition Assay Compounds are screened in the following manner for their ability to inhibit Aurora2 using a standard coupled enzyme assay (Fox et al (1998) Protein Sci 7, 2249). To an assay stock buffer solution containing 0. IM HEPES 7.5, 10 mM MgCl2, 1 mM DTT, 25 mM NaCl, 2.5 mM phosphoenolpyruvate, 300 mM NADH, 30 mg/ml pyruvate kinase, 10 mg/ml lactate dehydrogenase, 40 mM ATP, and 800 μM peptide (LRRASLG, American Peptide, Sunnyvale, CA) is added a DMSO solution of a compound of the present invention to a final concentration of 30 μM. The resulting mixture is incubated at 30 °C for 10 minutes. The reaction was initiated by the addition of 10 μL of Aurora2 stock solution to give a final concentration of 70 nM in the assay. The rates of reaction are obtained by monitoring absorbance at 340 nm over a 5 minute read time at 30 °C using a BioRad Ultramark plate reader (Hercules, CA) . The IC50 values are determined from the rate data as a function of inhibitor concentration.
Table 5 shows the results of the activity of selected compounds of this invention in the Aurora2 inhibition assay. The compound numbers correspond to the compound numbers in Table 1. Compounds having an IC50 less than 0.5 micromolar (μM) are rated "A", compounds having an IC50 between 0.5 and 2 μM are rated "B" and compounds having an IC50 greater than 2 μM are rated "C" .
Table 5. Aurora2 Activity of Selected Compounds
Figure imgf000049_0001
Figure imgf000050_0001
Example 7 Syk Inhibition Assay Compounds were screened for their ability to inhibit Syk using a standard coupled enzyme assay (Fox et al (1998) Protein Sci 7, 2249) . Reactions were carried out in 100 mM HEPES pH 7.5, 10 mM MgCl2, 25 mM NaCl, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay were 200 μM ATP (Sigma chemical Co.) and 4 μM poly Gly-Tyr peptide (Sigma Chemical Co.) . Assays were carried out at 30 °C and 200 nM Syk. Final concentrations of the components of the coupled enzyme system were 2.5 mM phosphoenolpyruvate, 300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase . An assay stock buffer solution was prepared containing all of the reagents listed above, with the exception of Syk, DTT and the test compound of interest. 56 μl of the test reaction was placed in a 96 well plate followed by the addition of 1 μl of 2 mM DMSO stock containing the test compound (final compound concentration 30 μM) . The plate was pre-incubated for -10 minutes at 30 °C and the reaction initiated by the addition of 10 μl of enzyme (final concentration 25 nM) . Rates of reaction were obtained using a BioRad Ultramark plate reader (Hercules, CA) over a 5 minute read time at 30 "C. Compounds showing >50 % inhibition versus standard wells containing DMSO, but no compound, were titrated and IC50's determined using a similar protocol.
Table 6 shows the results of the activity of selected compounds of this invention in the Syk inhibition assay. The compound numbers correspond to the compound numbers in Table 1. Compounds having an IC50 less than 0.5 micromolar (μM) are rated "A", compounds having an IC50 between 0.5 and 2 μM are rated "B" and compounds having an IC50 greater than 2 μM are rated "C" .
Table 6. Syk Activity of Selected Compounds
Figure imgf000051_0001
While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example .

Claims

CLAIMSWe claim:
1. A compound of formula I :
Figure imgf000053_0001
I or a pharmaceutically acceptable derivative thereof, wherein:
R1 is selected from R, halogen, CN, N02, or TR; T is an optionally substituted Cι-C4 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by O, N(R), C (O) , S, SO, or S02; each R is independently selected from hydrogen or an optionally substituted C -6 aliphatic group, wherein: two R bound to the same nitrogen atom are optionally taken together with the nitrogen to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms, in addition to the nitrogen bound thereto, independently selected from nitrogen, oxygen, or sulfur; Ar1 is an optionally substituted ring selected from: (a) a 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially unsaturated, or aryl ring; (b) a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
Ar1 is optionally substituted by one to four substituents selected from the group consisting of:
(a) one group selected from QR. Ar2, or QAr2; and
(b) up to four R2 groups; each Q is independently selected from a valence bond or an optionally substituted Cι_6 alkylidene chain, wherein: one or two non-adjacent methylene units of Q are optionally and independently replaced by -0-, -S-, -NR-, -C(O)-, -C02-, -C(0)NR-, -0C(0)NR-, -C(0)C(0)-, -NRC(O)-, NRC02-, -NRC(0)NR-, -S(O)-, -SO2-, -NRSO2-, -SO2NR-, or -NRSO2NR-; each Ar2 is an optionally substituted ring independently selected from: :
(a) a 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially unsaturated, or aryl ring;
(b) a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein: Ar2 is optionally substituted by one to four R2 groups ; and each R2 is independently selected from R, halogen, N02, CN, OR, SR, N(R)2, NRCOR, NRCON(R)2, NRC02R, C(0)R, C02R, CON(R)2, OC(0)N(R)2, SOR, S02R, S02N(R)2, NRS02R, NRS02N(R)2, C(0)C(0)R, or C (0) CH2C (O) R; wherein: two R2 on adjacent positions on Ar1 or Ar2 are optionally taken together to form a saturated, partially unsaturated, or fully unsaturated 4-6 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; provided that :
(a) when Ar1 is phenyl, two R2 are not simultaneously OR in the meta and para positions of Ar1; and
(b) R1 is other than CN.
2. The compound according to claim 1, wherein Ar1 is a ring selected from:
(a) a phenyl, indanyl, or naphthyl ring;
(b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic heteroaryl ring having 1-2 nitrogens, wherein:
Ar1 is substituted by one to four substituents selected from the group consisting of:
(a) one group selected from QR, Ar2, or QAr2; and
(b) up to four R2 groups.
3. The compound according to claim 2, wherein: Ar1 is selected from a phenyl, indanyl, naphthyl, pyrimidinyl, or pyridyl ring.
4. The compound according to either of claims 2 or 3, wherein:
Ar1 is substituted by one to four substituents selected from the group consisting of:
(a) one group selected from QR or QAr2; and
(b) up to four R2 groups; wherein: each R2 is independently selected from halogen, CN, C02R, R, N02, OR, haloalkyl, S02N(R)2, or N(R)2; each Q is independently selected from a Cι-4 alkylidene chain wherein one or two methylene units of Q are optionally replaced by 0, NH, NHCO, NHC02, NHS02, or CONH; and
Ar2 is is a 3-6 membered carbocyclic ring or an optionally substituted phenyl or 5-6 membered heterocyclic or heteroaryl ring having one to two heteroatoms independently selected from nitrogen, oxygen, or sulfur.
5. The compound according to either of claims 2 or 3, wherein:
Ar1 is substituted by Ar2 and optionally substituted with 1-2 R2 substituents, wherein: each Ar2 is an optionally substituted ring independently selected from: :
(a) a phenyl, indanyl, or naphthyl ring;
(b) a 5-6 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic or 9-10 membered bicyclic heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, nitrogen, or sulfur, wherein:
Ar2 is optionally substituted with 1-2 R2 groups ; and each R2 is independently selected from R, halogen, N02, CN, OR, SR, N(R)2, C(0)R, S02N(R)2, or S02R.
6. A compound selected from the following Table 1 compounds :
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
7. A compound selected from the following Table 2 compounds :
Figure imgf000063_0001
Ila-l IIa-2
Figure imgf000063_0002
IIa-3 IIa-4
Figure imgf000063_0003
IIa-5 IIa-6
Figure imgf000063_0004
IIa-7 IIa-8
Figure imgf000063_0005
ιia-9 IIa-10
Figure imgf000063_0006
IIa-11 IIa-12
Figure imgf000063_0007
IIa-13 IIa-14
Figure imgf000064_0001
IIa-15 IIa-16
Figure imgf000064_0002
IIa-19 IIa-20
Figure imgf000064_0003
IIa-21 Ila- -22
Figure imgf000064_0004
IIa-23 IIa-24
Figure imgf000064_0005
IIa-25 IIa-26
Figure imgf000065_0001
IIa-27 IIa-28
Figure imgf000065_0002
IIa-29 IIa-30
Figure imgf000065_0003
IIa-31 IIa-32
Figure imgf000065_0004
IIa-33 IIa-34
Figure imgf000065_0005
IIa-35 IIa-36
Figure imgf000065_0006
IIa-37 IIa-38
Figure imgf000066_0001
IIa-39 IIa-40
Figure imgf000066_0002
IIa-41 IIa-42
Figure imgf000066_0003
IIa-43 IIa-44
Figure imgf000066_0004
IIa-45 IIa-46
Figure imgf000066_0005
IIa-47 IIa-48
Figure imgf000066_0006
IIa-49 IIa- 50
8. A composition comprising a compound according to claim 1, in an amount to detectably inhibit GSK3 , Aurora2 , or Syk protein kinase activity, and a pharmaceutically acceptable carrier, adjuvant, or vehicle .
9. The composition according to claim 8, additionally comprising an additional therapeutic agent selected from an anti-diabetic agent, a chemotherapeutic or anti-proliferative agent, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS) , a treatment for asthma, an agent for treating schizophrenia, an anti -inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an agent for treating a blood disorder, or an agent for treating an immunodeficiency disorder.
10. A method of inhibiting GSK3 , Aurora2 , or Syk kinase activity in a biological sample, comprising the step of contacting said biological sample with: a) a composition according to claim 8; or b) a compound of formula I:
Figure imgf000067_0001
I or a pharmaceutically acceptable derivative thereof, wherein : R1 is selected from R, halogen, CN, N02, or TR; T is an optionally substituted Cι-C4 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by 0, N(R), C(0), S, SO, or S02; each R is independently selected from hydrogen or an optionally substituted Cι-6 aliphatic group, wherein: two R bound to the same nitrogen atom are optionally taken together with the nitrogen to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms, in addition to the nitrogen bound thereto, independently selected from nitrogen, oxygen, or sulfur; Ar1 is an optionally substituted ring selected from:
(a) a 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially unsaturated, or aryl ring;
(b) a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
Ar1 is optionally substituted by one to four substituents selected from:
(a) one group selected from QR, Ar2, or QAr2; and (b) up to four R2 groups; each Q is independently selected from a valence bond or an optionally substituted Cι-6 alkylidene chain, wherein: one or two non-adjacent methylene units of Q are optionally and independently replaced by -0-, -S-, -NR-, -C(O)-, -C02-, -C(0)NR-, -OC(0)NR-, -C(0)C(0)-, -NRC(O)-, NRC02-, -NRC(0)NR-, -S(O)-, -S02-, -NRSO2-, -SO2NR-, or -NRSO2NR-; each Ar2 is an optionally substituted ring independently selected from: :
(a) a 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially unsaturated, or aryl ring;
(b) a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
Ar2 is optionally substituted by one to four R2 groups ; and each R2 is independently selected from R, halogen, N02, CN, OR, SR, N(R)2, NRCOR, NRCON(R)2, NRC02R, C(0)R, C02R, CON(R)2, OC(0)N(R)2, SOR, S02R, S02N(R)2, NRS02R, NRS02N(R)2, C(0)C(0)R, or C (0) CH2C (O) R; wherein: two R2 on adjacent positions on Ar1 or Ar2 are optionally taken together to form a saturated, partially unsaturated, or fully unsaturated 4-6 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
11. A method of treating or lessening the severity of a GSK3-, Aurora2-, or Syk-mediated disease or condition in a patient, comprising the step of administering to said patient: a) a composition according to claim 8; or b) a compound of formula I
Figure imgf000070_0001
I or a pharmaceutically acceptable derivative thereof, wherein:
R1 is selected from R, halogen, CN, N02, or TR; T is an optionally substituted Cι-C4 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by O, N(R), C(O), S, SO, or S02; each R is independently selected from hydrogen or an optionally substituted Cι-6 aliphatic group, wherein: two R bound to the same nitrogen atom are optionally taken together with the nitrogen to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms, in addition to the nitrogen bound thereto, independently selected from nitrogen, oxygen, or sulfur; Ar1 is an optionally substituted ring selected from:
(a) a 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially unsaturated, or aryl ring;
(b) a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein: Ar1 is optionally substituted by one to four substituents selected from:
(a) one group selected from QR, Ar2, or QAr2; and (b) up to four R2 groups; each Q is independently selected from a valence bond or an optionally substituted Cι_6 alkylidene chain, wherein: one or two non-adjacent methylene units of Q are optionally and independently replaced by -O- , -S-, -NR-, -C(O)-, -C02-, -C(0)NR-, -OC(0)NR-, -C(0)C(0)-, -NRC(O)-, NRC02-, -NRC(0)NR-, -S(O)-, -S02-, -NRS02-, -S02NR-, or -NRS02NR- ; each Ar2 is an optionally substituted ring independently selected from: :
(a) a 3-8 membered monocyclic or 8-10 membered bicyclic saturated, partially unsaturated, or aryl ring;
(b) a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or
(c) a 5-6 membered monocyclic or 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
Ar2 is optionally substituted by one to four R2 groups ; and each R2 is independently selected from R, halogen, N02, CN, OR, SR, N(R)2, NRCOR, NRC0N(R)2, NRC02R, C(0)R, C02R, C0N(R)2, 0C(0)N(R)2, SOR, S02R, S02N(R)2, NRS02R, NRS02N(R)2, C(0)C(0)R, or C (O) CH2C (0) R; wherein: two R2 on adjacent positions on Ar1 or Ar2 are optionally taken together to form a saturated, partially unsaturated, or fully unsaturated 4-6 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
12. The method according to claim 11, wherein said GSK3-mediated disease is selected from diabetes, a neurodegenerative disorder, a CNS disorder, Alzheimer's disease, Huntington' s, Parkinson's, AIDS associated dementia, amyotrophic lateral sclerosis (7AML) , multiple sclerosis (MS) , stroke, schizophrenia, cardiomycete hypertrophy, a manic depressive disorder, or baldness.
13. The method according to claim 11, wherein said Aurora2-mediated disease is selected from cancer.
14. The method according to claim 11, wherein said Syk-mediated disease is selected from an allergic disorder.
15. The method according to claim 11, comprising the additional step of administering to said patient an additional therapeutic agent selected from an anti- diabetic agent, a chemotherapeutic or anti-proliferatic agent, a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS) , a treatment for asthma, an agent for treating schizophrenia, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating liver disease, an agent reating a blood disorder, or an agent for treating munodeficiency disorder, wherein: said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.
PCT/US2002/016352 2001-05-31 2002-05-23 Thiazole compounds useful as inhibitors of protein kinases Ceased WO2002096905A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE60214703T DE60214703T2 (en) 2001-06-01 2002-05-23 THIAZOL COMPOUNDS SUITABLE AS INHIBITORS OF PROTEIN KINASES
CA2446756A CA2446756C (en) 2001-06-01 2002-05-23 Thiazole compounds useful as inhibitors of protein kinase
MXPA03010961A MXPA03010961A (en) 2001-05-31 2002-05-23 Thiazole compounds useful as inhibitors of protein kinases.
EP02737123A EP1392684B1 (en) 2001-06-01 2002-05-23 Thiazole compounds useful as inhibitors of protein kinases
JP2003500084A JP4523271B2 (en) 2001-06-01 2002-05-23 Thiazole compounds useful as inhibitors of protein kinases
HK04106666.6A HK1065033B (en) 2001-06-01 2002-05-23 Thiazole compounds useful as inhibitors of protein kinases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29515801P 2001-06-01 2001-06-01
US60/295,158 2001-06-01

Publications (2)

Publication Number Publication Date
WO2002096905A1 true WO2002096905A1 (en) 2002-12-05
WO2002096905A8 WO2002096905A8 (en) 2005-07-28

Family

ID=35781455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016352 Ceased WO2002096905A1 (en) 2001-05-31 2002-05-23 Thiazole compounds useful as inhibitors of protein kinases

Country Status (8)

Country Link
US (2) US7256190B2 (en)
EP (1) EP1392684B1 (en)
JP (2) JP4523271B2 (en)
AT (1) ATE339418T1 (en)
CA (1) CA2446756C (en)
DE (1) DE60214703T2 (en)
ES (1) ES2274035T3 (en)
WO (1) WO2002096905A1 (en)

Cited By (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041813A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2004056368A1 (en) * 2002-12-19 2004-07-08 Cyclacel Limited Therapeutic applications of 2-substituted 4-heteroarylryrimidines
WO2004080977A1 (en) * 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated 4-substituted-5-cyano-1h-pyrimidin-6-(thi)ones as gsk-3 inhibitors
WO2004087699A3 (en) * 2003-03-25 2004-12-09 Vertex Pharma Thiazoles useful as inhibitors of protein kinases
WO2005113550A1 (en) * 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation Aminopyrimidine derivative and medicinal use thereof
WO2006044457A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
WO2006093247A1 (en) * 2005-02-28 2006-09-08 Japan Tobacco Inc. NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY
US7151113B2 (en) 2003-05-01 2006-12-19 Bristol Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US7169771B2 (en) 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US7226923B2 (en) 2004-09-24 2007-06-05 Hoffman-La Roche Inc. Phthalazinone derivatives
JP2007520540A (en) * 2004-02-06 2007-07-26 サイクラセル リミテッド Compound
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
JP2008500320A (en) * 2004-05-26 2008-01-10 サイクラセル リミテッド 2-Substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
JP2008510839A (en) * 2004-08-25 2008-04-10 ターゲジェン インコーポレーティッド Heterocyclic compounds and methods of use
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
JP2009503060A (en) * 2005-08-05 2009-01-29 イル−ヤン ファーム カンパニー リミテッド N-phenyl-2-pyrimidin-amine derivative and process for its preparation
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
RU2363699C2 (en) * 2005-02-28 2009-08-10 Джапан Тобакко Инк. New aminopyridin derivative with inhibition activity in relation to syk
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US7576053B2 (en) 2005-06-13 2009-08-18 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8158621B2 (en) 2002-07-29 2012-04-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8309566B2 (en) 2008-02-15 2012-11-13 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US8404692B2 (en) 2005-10-14 2013-03-26 Cyclacel Limited Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds
US8551984B2 (en) 2009-12-17 2013-10-08 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
WO2013156608A1 (en) 2012-04-20 2013-10-24 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
WO2014063068A1 (en) * 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US8735417B2 (en) 2009-12-17 2014-05-27 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9290490B2 (en) 2011-05-10 2016-03-22 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US9499534B2 (en) 2013-04-26 2016-11-22 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US9505784B2 (en) 2009-06-12 2016-11-29 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US9598405B2 (en) 2012-12-21 2017-03-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
US9745295B2 (en) 2013-04-26 2017-08-29 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US10059690B2 (en) 2014-04-04 2018-08-28 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US12466828B2 (en) 2019-10-11 2025-11-11 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022605A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
ATE352714T1 (en) * 2005-06-17 2007-02-15 Magneti Marelli Powertrain Spa FUEL INJECTION VALVE
EP2079739A2 (en) * 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA019524B1 (en) * 2007-05-04 2014-04-30 Айрм Ллк COMPOUNDS AND COMPOSITIONS AS c-kit AND PDGFR KINASE INHIBITORS
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013138617A1 (en) 2012-03-16 2013-09-19 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
MX371331B (en) 2012-04-24 2020-01-27 Vertex Pharma Dna-pk inhibitors.
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
ME03336B (en) 2013-03-12 2019-10-20 Vertex Pharma DNA-PK INHIBITORS
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
JP6408569B2 (en) 2013-10-17 2018-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ (S) -N-methyl-8- (1-((2′-methyl- [4,5′-bipyrimidin] -6-yl) amino) propan-2-yl) quinoline- as DNA-PK inhibitor Co-crystal of 4-carboxamide and its deuterated derivative
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
WO2015191630A1 (en) * 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
TWI703133B (en) 2014-12-23 2020-09-01 美商艾克斯基製藥公司 3,5-diaminopyrazole kinase inhibitors
EP3231434A1 (en) 2016-04-14 2017-10-18 Fundacio Centre de Regulacio Genomica Method of treatment of parkinsonism
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated CANCER TREATMENT METHOD USING A COMBINATION OF DNA DAMAGING AGENTS AND DNA-PK INHIBITORS
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO2000078731A1 (en) * 1999-06-18 2000-12-28 Celltech R&D Limited 5-cyano-2-aminopyrimidine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CA2441733A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AU2002338642A1 (en) * 2001-04-13 2002-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2002092573A2 (en) * 2001-05-16 2002-11-21 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
MXPA03010961A (en) * 2001-05-31 2004-02-27 Vertex Pharma Thiazole compounds useful as inhibitors of protein kinases.
US20030207873A1 (en) * 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958935A (en) * 1995-11-20 1999-09-28 Celltech Therapeutics Limited Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
WO2000078731A1 (en) * 1999-06-18 2000-12-28 Celltech R&D Limited 5-cyano-2-aminopyrimidine derivatives

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158621B2 (en) 2002-07-29 2012-04-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
WO2004041813A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2004056368A1 (en) * 2002-12-19 2004-07-08 Cyclacel Limited Therapeutic applications of 2-substituted 4-heteroarylryrimidines
CN100425239C (en) * 2002-12-19 2008-10-15 西克拉塞尔有限公司 Therapeutic applications of 2-substituted 4-heteroarylpyrimidines
JP2006515588A (en) * 2002-12-19 2006-06-01 サイクラセル・リミテッド Therapeutic application of 2-substituted 4-heteroarylpyrimidines
US7323482B2 (en) 2003-02-06 2008-01-29 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US7169771B2 (en) 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
WO2004080977A1 (en) * 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated 4-substituted-5-cyano-1h-pyrimidin-6-(thi)ones as gsk-3 inhibitors
US7217712B2 (en) 2003-03-12 2007-05-15 Vertex Pharmaceuticals Incorporated 4-Substituted-5-cyano-1H-pyrimidin-6-(thi)ones as GSK-3 inhibitors
WO2004087699A3 (en) * 2003-03-25 2004-12-09 Vertex Pharma Thiazoles useful as inhibitors of protein kinases
JP2006522125A (en) * 2003-03-25 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド Thiazoles useful as protein kinase inhibitors
US7276502B2 (en) 2003-03-25 2007-10-02 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
US7592338B2 (en) 2003-05-01 2009-09-22 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US7253170B2 (en) 2003-05-01 2007-08-07 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US7151113B2 (en) 2003-05-01 2006-12-19 Bristol Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2007520540A (en) * 2004-02-06 2007-07-26 サイクラセル リミテッド Compound
WO2005113550A1 (en) * 2004-05-20 2005-12-01 Mitsubishi Pharma Corporation Aminopyrimidine derivative and medicinal use thereof
JP2008500320A (en) * 2004-05-26 2008-01-10 サイクラセル リミテッド 2-Substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2008510839A (en) * 2004-08-25 2008-04-10 ターゲジェン インコーポレーティッド Heterocyclic compounds and methods of use
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
US7226923B2 (en) 2004-09-24 2007-06-05 Hoffman-La Roche Inc. Phthalazinone derivatives
WO2006044457A1 (en) * 2004-10-13 2006-04-27 Wyeth N-benzenesulfonyl substituted anilino-pyrimidine analogs
US7799915B2 (en) 2004-10-13 2010-09-21 Wyeth Llc Anilino-pyrimidine analogs
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8288536B2 (en) 2004-10-15 2012-10-16 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006093247A1 (en) * 2005-02-28 2006-09-08 Japan Tobacco Inc. NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY
RU2363699C2 (en) * 2005-02-28 2009-08-10 Джапан Тобакко Инк. New aminopyridin derivative with inhibition activity in relation to syk
KR100917511B1 (en) 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Novel aminopyridine compound with syk inhibitory activity
US7803801B2 (en) 2005-02-28 2010-09-28 Japan Tobacco, Inc. Aminopyridine compounds having Syk inhibitory activity
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
US7576053B2 (en) 2005-06-13 2009-08-18 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
JP2009503060A (en) * 2005-08-05 2009-01-29 イル−ヤン ファーム カンパニー リミテッド N-phenyl-2-pyrimidin-amine derivative and process for its preparation
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8404692B2 (en) 2005-10-14 2013-03-26 Cyclacel Limited Pyrimidin-4-yl-3, 4-dihydro-2H-pyrrolo [1,2A] pyrazin-1-one compounds
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
WO2007132221A1 (en) * 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
US8278450B2 (en) 2007-04-18 2012-10-02 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
US8735418B2 (en) 2008-02-15 2014-05-27 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US8309566B2 (en) 2008-02-15 2012-11-13 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US9624229B2 (en) 2008-02-15 2017-04-18 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
EP2177510A1 (en) 2008-10-17 2010-04-21 Universität des Saarlandes Allosteric protein kinase modulators
US9505784B2 (en) 2009-06-12 2016-11-29 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US8551984B2 (en) 2009-12-17 2013-10-08 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
US8735417B2 (en) 2009-12-17 2014-05-27 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
US8759366B2 (en) 2009-12-17 2014-06-24 Merck Sharp & Dohme Corp. Aminopyrimidines as SYK inhibitors
US11826365B2 (en) 2009-12-29 2023-11-28 Dana-Farber Cancer Institute, Inc. Type II raf kinase inhibitors
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US10391094B2 (en) 2010-11-07 2019-08-27 Impact Biomedicines, Inc. Compositions and methods for treating myelofibrosis
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
US9120785B2 (en) 2011-05-10 2015-09-01 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
US9290490B2 (en) 2011-05-10 2016-03-22 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US10981903B2 (en) 2011-11-17 2021-04-20 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US10144730B2 (en) 2011-11-17 2018-12-04 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
WO2013156608A1 (en) 2012-04-20 2013-10-24 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
WO2014063068A1 (en) * 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10787436B2 (en) 2012-10-18 2020-09-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9624210B2 (en) 2012-12-12 2017-04-18 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase (Syk) inhibitors
US9598405B2 (en) 2012-12-21 2017-03-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9745295B2 (en) 2013-04-26 2017-08-29 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9499534B2 (en) 2013-04-26 2016-11-22 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US10906889B2 (en) 2013-10-18 2021-02-02 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US11040957B2 (en) 2013-10-18 2021-06-22 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
US10106526B2 (en) 2014-04-04 2018-10-23 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10059690B2 (en) 2014-04-04 2018-08-28 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US12168663B2 (en) 2014-12-23 2024-12-17 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US12098154B2 (en) 2015-03-27 2024-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11325910B2 (en) 2015-03-27 2022-05-10 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US12312331B2 (en) 2019-08-14 2025-05-27 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US12466828B2 (en) 2019-10-11 2025-11-11 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Also Published As

Publication number Publication date
DE60214703D1 (en) 2006-10-26
WO2002096905A8 (en) 2005-07-28
CA2446756A1 (en) 2002-12-05
HK1065033A1 (en) 2005-02-08
ATE339418T1 (en) 2006-10-15
US20070249645A1 (en) 2007-10-25
ES2274035T3 (en) 2007-05-16
EP1392684B1 (en) 2006-09-13
US7488727B2 (en) 2009-02-10
JP4523271B2 (en) 2010-08-11
EP1392684A1 (en) 2004-03-03
US7256190B2 (en) 2007-08-14
CA2446756C (en) 2011-03-08
DE60214703T2 (en) 2007-09-13
JP2006516110A (en) 2006-06-22
JP2009269932A (en) 2009-11-19
US20050004152A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
CA2446756C (en) Thiazole compounds useful as inhibitors of protein kinase
US6762179B2 (en) Thiazole compounds useful as inhibitors of protein kinase
CA2432872C (en) Pyrazole compounds useful as protein kinase inhibitors
US6825190B2 (en) Protein kinase inhibitors and uses thereof
EP1417205B1 (en) Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
AU2002246754A1 (en) Pyrazole compounds useful as protein kinase inhibitors
HK1065033B (en) Thiazole compounds useful as inhibitors of protein kinases
HK1060557B (en) Pyrazole compounds useful as protein kinase inhibitors
HK1062433B (en) Pyrazole compounds useful as protein kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2446756

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002737123

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/010961

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003500084

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002737123

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 49/2002 UNDER (30) REPLACE "60/295,196" BY "60/295,158"

WWG Wipo information: grant in national office

Ref document number: 2002737123

Country of ref document: EP